PE20220970A1 - Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones - Google Patents
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulacionesInfo
- Publication number
- PE20220970A1 PE20220970A1 PE2022000318A PE2022000318A PE20220970A1 PE 20220970 A1 PE20220970 A1 PE 20220970A1 PE 2022000318 A PE2022000318 A PE 2022000318A PE 2022000318 A PE2022000318 A PE 2022000318A PE 20220970 A1 PE20220970 A1 PE 20220970A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- formulations
- compound
- pyrazol
- discloses
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 229940077388 benzenesulfonate Drugs 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001733 carboxylic acid esters Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000002467 interleukin receptors Human genes 0.000 abstract 1
- 108010093036 interleukin receptors Proteins 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- -1 pyrazole derivative compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894547P | 2019-08-30 | 2019-08-30 | |
| PCT/US2020/048528 WO2021041898A1 (en) | 2019-08-30 | 2020-08-28 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220970A1 true PE20220970A1 (es) | 2022-06-10 |
Family
ID=72473975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000318A PE20220970A1 (es) | 2019-08-30 | 2020-08-28 | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones |
Country Status (21)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022545542A (ja) | 2019-08-30 | 2022-10-27 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法 |
| WO2022187303A1 (en) * | 2021-03-03 | 2022-09-09 | Rigel Pharmaceuticals, Inc. | A method for treating a disease or condition using a pyrazole compound or formulation thereof |
| EP4399208A4 (en) * | 2021-09-08 | 2025-07-16 | Rigel Pharmaceuticals Inc | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE CONDITIONS ASSOCIATED WITH RESPIRATORY VIRUS INFECTION |
| ES3075943T3 (en) * | 2022-03-23 | 2026-08-10 | Rigel Pharmaceuticals Inc | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
| WO2026122888A1 (en) * | 2024-12-06 | 2026-06-11 | Rigel Pharmaceuticals, Inc. | Pharmaceutical compositions comprising 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol -4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate or its salts |
| US20260159538A1 (en) * | 2024-12-06 | 2026-06-11 | Rigel Pharmaceuticals, Inc. | Solid forms of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate and salts thereof, and their pharmaceutical compositions and uses |
| US20260158048A1 (en) | 2024-12-06 | 2026-06-11 | Rigel Pharmaceuticals, Inc. | Methods of treatment |
| CN119950825B (zh) * | 2025-03-13 | 2025-07-22 | 北京工业大学 | 基于压电驱动的自适应释药电纺覆膜气管支架的制备方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| CA2031376A1 (en) | 1989-12-04 | 1991-06-05 | Bahram Farhadieh | Single layer transdermal drug administration system |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| CA2123809A1 (en) | 1991-12-18 | 1993-06-24 | Debra L. Wilfong | Multilayered barrier structures |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| EP1836188A1 (en) | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| WO2006070202A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
| SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
| US8987309B2 (en) | 2009-04-17 | 2015-03-24 | The Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles |
| EP2243481A1 (en) | 2009-04-24 | 2010-10-27 | PamGene B.V. | Irak kinase family as novel drug target for Alzheimer |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| CA2794801C (en) | 2010-04-07 | 2019-01-15 | F. Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| RU2632900C2 (ru) | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| WO2012072685A1 (en) | 2010-12-02 | 2012-06-07 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Irak-related interventions and diagnosis |
| HUE029617T2 (en) | 2010-12-20 | 2017-03-28 | Merck Serono Sa | Indazolyl triazole derivatives as IRAK inhibitors |
| EP3239154A1 (en) | 2011-01-10 | 2017-11-01 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CN103347873A (zh) | 2011-02-09 | 2013-10-09 | 日产化学工业株式会社 | 吡唑衍生物和有害生物防除剂 |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| EP2760857A1 (en) | 2011-09-27 | 2014-08-06 | F.Hoffmann-La Roche Ag | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| TW201728592A (zh) | 2012-01-10 | 2017-08-16 | 林伯士艾瑞斯公司 | Ｉｒａｋ抑制劑及其用途 |
| WO2014048939A1 (en) | 2012-09-26 | 2014-04-03 | F. Hoffmann-La Roche Ag | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| WO2014058691A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| JP6483624B2 (ja) | 2013-02-07 | 2019-03-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピリダジノン−アミド誘導体 |
| ES2639717T3 (es) | 2013-02-07 | 2017-10-30 | Merck Patent Gmbh | Derivados de piridazinona macrocíclicos |
| ES2728403T3 (es) | 2014-01-09 | 2019-10-24 | Merck Patent Gmbh | Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK |
| LT3221306T (lt) | 2014-11-20 | 2020-03-10 | Merck Patent Gmbh | Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas |
| DK3286181T3 (da) * | 2015-04-22 | 2021-04-06 | Rigel Pharmaceuticals Inc | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne |
| CN110099899B (zh) * | 2016-10-26 | 2024-01-02 | 里格尔药品股份有限公司 | 用作irak抑制剂的噁唑衍生物及其制备方法 |
| JP2022545542A (ja) * | 2019-08-30 | 2022-10-27 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法 |
-
2020
- 2020-08-28 JP JP2022513277A patent/JP2022545542A/ja active Pending
- 2020-08-28 BR BR112022003564A patent/BR112022003564A2/pt unknown
- 2020-08-28 EP EP20771685.3A patent/EP4003990A1/en active Pending
- 2020-08-28 PH PH1/2022/550466A patent/PH12022550466A1/en unknown
- 2020-08-28 CR CR20220085A patent/CR20220085A/es unknown
- 2020-08-28 AU AU2020335903A patent/AU2020335903B2/en active Active
- 2020-08-28 MX MX2022002292A patent/MX2022002292A/es unknown
- 2020-08-28 IL IL290882A patent/IL290882B2/en unknown
- 2020-08-28 CA CA3152264A patent/CA3152264A1/en active Pending
- 2020-08-28 TW TW109129543A patent/TWI870449B/zh active
- 2020-08-28 CN CN202511306178.3A patent/CN121159524A/zh active Pending
- 2020-08-28 AR ARP200102424A patent/AR119857A1/es unknown
- 2020-08-28 PY PY202002049213A patent/PY2049213A/es unknown
- 2020-08-28 US US17/006,150 patent/US11370787B2/en active Active
- 2020-08-28 CN CN202080061311.2A patent/CN114364674B/zh active Active
- 2020-08-28 PE PE2022000318A patent/PE20220970A1/es unknown
- 2020-08-28 WO PCT/US2020/048528 patent/WO2021041898A1/en not_active Ceased
-
2022
- 2022-02-23 EC ECSENADI202214379A patent/ECSP22014379A/es unknown
- 2022-02-25 DO DO2022000047A patent/DOP2022000047A/es unknown
- 2022-02-27 JO JOP/2022/0050A patent/JOP20220050A1/ar unknown
- 2022-02-28 SA SA522431791A patent/SA522431791B1/ar unknown
- 2022-03-15 CO CONC2022/0002993A patent/CO2022002993A2/es unknown
- 2022-05-18 US US17/747,384 patent/US20220306620A1/en not_active Abandoned
-
2023
- 2023-08-24 US US18/237,824 patent/US12441723B2/en active Active
-
2025
- 2025-11-25 JP JP2025203023A patent/JP2026053335A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020335903B2 (en) | 2026-06-11 |
| TWI870449B (zh) | 2025-01-21 |
| US20230399326A1 (en) | 2023-12-14 |
| PH12022550466A1 (en) | 2023-03-06 |
| JP2026053335A (ja) | 2026-03-25 |
| CN121159524A (zh) | 2025-12-19 |
| US12441723B2 (en) | 2025-10-14 |
| JOP20220050A1 (ar) | 2023-01-30 |
| SA522431791B1 (ar) | 2025-04-14 |
| IL290882B1 (en) | 2025-11-01 |
| IL290882B2 (en) | 2026-03-01 |
| BR112022003564A2 (pt) | 2022-05-17 |
| MX2022002292A (es) | 2022-06-02 |
| CA3152264A1 (en) | 2021-03-04 |
| CN114364674A (zh) | 2022-04-15 |
| US20210061798A1 (en) | 2021-03-04 |
| IL290882A (en) | 2022-04-01 |
| US11370787B2 (en) | 2022-06-28 |
| WO2021041898A1 (en) | 2021-03-04 |
| US20220306620A1 (en) | 2022-09-29 |
| PY2049213A (es) | 2021-05-05 |
| DOP2022000047A (es) | 2022-04-29 |
| ECSP22014379A (es) | 2022-05-31 |
| JP2022545542A (ja) | 2022-10-27 |
| KR20220054626A (ko) | 2022-05-03 |
| CN114364674B (zh) | 2025-10-03 |
| AR119857A1 (es) | 2022-01-19 |
| CR20220085A (es) | 2022-04-19 |
| EP4003990A1 (en) | 2022-06-01 |
| TW202122393A (zh) | 2021-06-16 |
| AU2020335903A1 (en) | 2022-03-24 |
| CO2022002993A2 (es) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| ME00052B (me) | Derivati pirazolokarbokiseline kiseline, njihova priprema farmaceutske kompozicije sa sadržajem istih | |
| MX2021012756A (es) | Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este. | |
| AR119857A1 (es) | Compuestos de pirazol, formulaciones de los mismos y su uso para la inhibición de una proteína irak | |
| ATE540932T1 (de) | Hydantoin-derivate als antibakterielle wirkstoffe | |
| CO2023004420A2 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl | |
| JP2016504400A (ja) | ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用 | |
| BR112022018515A2 (pt) | Terapia de combinação para leucemia mieloide aguda | |
| PE20251236A1 (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| MX2021003662A (es) | Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo. | |
| PY2228191A (es) | Nuevos derivados de heteroaril aminopropanol | |
| BR112022001922A2 (pt) | Compostos de heteroarila de anel fundido como inibidores de ripk1 | |
| CL2024001481A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| PE20252585A1 (es) | Compuestos de degradacion de la cinasa 2 del receptor acoplado a proteina g ( grk2) y usos de estos | |
| WO2014022382A2 (en) | Antibacterial protein kinase inhibitors | |
| AR133698A1 (es) | COMPUESTOS Y COMPOSICIONES COMO AGENTES DEGRADANTES DE CBP / p300 Y USOS DE ESTOS | |
| PE20252682A1 (es) | Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlrp3 para el tratamiento de, por ejemplo, enfermedades inflamatorias | |
| HUE032472T2 (en) | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | |
| PE20251177A1 (es) | Inhibidores heterociclicos de sik | |
| JP5682555B2 (ja) | アルツハイマー病の治療剤又は予防剤 | |
| JP2017537104A (ja) | 変形性関節症におけるσ受容体リガンドの使用 | |
| MX2024013889A (es) | Derivado de anillo de benceno sustituido con imidazopiridazina, método de preparación, composición farmacéutica y uso |